GlassScriptPhysician profile
Sagar Patel
NPI 1710349873
$85,314.16
in general payments reported to CMS, 2019-2025
44 companies · $62K in 2025
The $62K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $200 · 2022: $1,499 · 2023: $4,214 · 2024: $17K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $18K · Travel and Lodging: $6,162 · Education: $83.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,378.50 |
| Food and Beverage | $17,865.53 |
| Travel and Lodging | $6,162.44 |
| Education | $83.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $26,874.11 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $21,885.93 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $20,395.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $3,531.82 | 2022-2025 | |
| Janssen Biotech, INC. | $2,034.13 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,368.31 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,000.80 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $873.04 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $846.24 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $833.86 | 2024-2025 | Zenpep |
| Celgene Corporation | $639.96 | 2022-2024 | Zeposia |
| Pfizer INC. | $582.15 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $489.80 | 2022-2025 | Dupixent |
| Vivus LLC | $466.24 | 2022-2025 | Pancreaze, Qsymia |
| Medtronic, INC. | $446.38 | 2022-2025 | Interstim, Linq II |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $437.80 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $342.75 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $209.61 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $202.91 | 2022-2024 | Linzess |
| Sandoz INC. | $165.24 | 2024 | Hyrimoz |
| Janssen Scientific Affairs, LLC | $148.92 | 2024 | Tremfya |
| Ferring Pharmaceuticals INC. | $140.12 | 2022-2025 | Rebyota |
| Blueprint Medicines Corporation | $126.27 | 2024-2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $122.43 | 2022-2025 | Ocaliva |
| Evoke Pharma, INC. | $108.89 | 2023-2025 | Gimoti |
| Novo Nordisk INC | $106.21 | 2023-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $96.92 | 2022-2024 | Givlaari |
| Merck Sharp & Dohme LLC | $94.32 | 2022-2024 | Dificid |
| Amgen INC. | $93.71 | 2023-2025 | Amjevita, Uplizna |
| Fresenius Kabi USA, LLC | $73.36 | 2023-2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $70.83 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.35 | 2024 | Cyltezo |
| Daiichi Sankyo INC. | $64.55 | 2022-2025 | Injectafer |
| Shield Therapeutics INC | $35.04 | 2024 | |
| Exact Sciences Corporation | $32.77 | 2023-2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $32.30 | 2022-2023 | Cre Pro |
| Organon LLC | $28.16 | 2024-2025 | Hadlima |
| Braintree Laboratories, INC. | $25.34 | 2022-2023 | Suflave |
| Alcresta Therapeutics, INC. | $25.24 | 2024 | Relizorb |
| Mirum Pharmaceuticals, INC. | $22.84 | 2025 | Livmarli |
| Echosens North America, INC. | $17.53 | 2023 | Fibroscan |
| Gilead Sciences, INC. | $15.15 | 2023 | |
| Redhill Biopharma INC. | $13.60 | 2023 | Aemcolo, Movantik, Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.